Nektar Therapeutics

top of page

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.

Bright Minds

2 days ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

Follow BiotechTV

Sponsors

Sponsor Spotlight